Celgene Corporation  

(Public, NASDAQ:CELG)   Watch this stock  
Find more results for celg
105.40
+4.90 (4.88%)
Real-time:   1:09PM EST
NASDAQ real-time data - Disclaimer
Currency in USD
Range 101.17 - 105.98
52 week 92.98 - 140.72
Open 101.84
Vol / Avg. 3.90M/7.44M
Mkt cap 83.91B
P/E 54.40
Div/yield     -
EPS 1.94
Shares 785.65M
Beta 1.26
Inst. own 82%
Apr 28, 2016
Q1 2016 Celgene Corp Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Feb 24, 2016
Celgene Corp at RBC Capital Markets Healthcare Conference - 9:00AM EST - Add to calendar
Feb 11, 2016
Celgene Corp at Leerink Partners Global Healthcare Conference - 8:55AM EST - Add to calendar
Jan 28, 2016
Q4 2015 Celgene Corp Earnings Release
Jan 28, 2016
Q4 2015 Celgene Corp Earnings Call
Jan 11, 2016
Celgene Corp at JPMorgan Healthcare Conference (Q&A)
Jan 11, 2016
Celgene Corp at JPMorgan Healthcare Conference
Dec 6, 2015
Celgene Corp at the American Society of Hematology Annual Meeting
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '15) 2015
Net profit margin 21.89% 17.31%
Operating margin 35.12% 24.36%
EBITD margin - 30.61%
Return on average assets - -
Return on average equity - -
Employees 6,012 -
CDP Score - 85 B

Address

86 Morris Ave
SUMMIT, NJ 07901-3915
United States - Map
+1-908-6739000 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Transcripts - SeekingAlpha

Description

Celgene Corporation (Celgene), together with its subsidiaries, is an integrated biopharmaceutical company engaged primarily in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation. The Company’s primary commercial stage products include REVLIMID (lenalidomide), ABRAXANE, POMALYST/IMNOVID, VIDAZA, azacitidine for injection (generic version of VIDAZA), THALOMID (sold as THALOMID or Thalidomide Celgene outside the United States), OTEZLA (apremilast) and ISTODAX (romidepsin). Celgene is involved in research in a range of scientific areas designed to deliver therapies, targeting areas, including intracellular signaling pathways, protein homeostasis and epigenetics in cancer and immune cells, immunomodulation in cancer and autoimmune diseases, and therapeutic application of cell therapies.

Officers and directors

Robert J. Hugin Executive Chairman of the Board
Age: 61
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Mark J. Alles Chief Executive Officer
Age: 56
Bio & Compensation  - Reuters
Peter N. Kellogg Chief Financial Officer, Executive Vice President
Age: 59
Bio & Compensation  - Reuters
Thomas O. Daniel M.D. Chairman - Celgene Research
Age: 61
Bio & Compensation  - Reuters
Jacqualyn A. Fouse Ph.D. President, Chief Operating Officer
Age: 54
Bio & Compensation  - Reuters
Scott A. Smith Global President - Inflammation & Immunology
Age: 53
Bio & Compensation  - Reuters
Rupert Vessey President - Research and Early Development
Bio & Compensation  - Reuters
Robert M. Hershberg M.D., Ph.D. Chief Scientific Officer
Age: 50
Bio & Compensation  - Reuters
Michael D. Casey Lead Independent Director
Age: 69
Bio & Compensation  - Reuters
Michael W. Bonney Director
Age: 57
Bio & Compensation  - Reuters